tradingview.comOCT 61 min read$NEO

StoneX maintains Buy rating on NeoGenomics, $20 price target

StoneX maintained a Buy rating on NeoGenomics with a $20 price target, implying a 4.5% upside from the Oct 5 close. The firm cited strong revenue growth potential due to the company's leadership in cancer diagnostic testing and attractive valuation relative to peers.

Original reporting

tradingview.com

Published Oct 6, 2026, 12:40 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 6, 2026, 12:52 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

StoneX maintains Buy rating on NeoGenomics, $20 price target — source image — Source · tradingview.com

Decision brief

The 30-second read

$NEOBullishMed

Why it matters

The rating and target provide a small upside thesis but lack a major catalyst.

Market read

Provides a modest bullish signal for NeoGenomics; limited broader market effect.

What to watch

Potential competitive pressure from larger diagnostics firms could limit upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst note from StoneX reiterating a Buy stance and setting a $20 price target for NeoGenomics.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NEOBullishMedium confidence

Context

StoneX maintained a Buy rating on NeoGenomics with a $20 price target, implying a 4.5% upside from the recent close.

Expected impact

likely modest upside as investors price in the $20 target

Evidence & confidence

The new target is only 4.5% above current price, so impact is limited but may attract short‑term buying.

Market effects

Sector

May reinforce bullish sentiment in the cancer diagnostics sector.

Regional

Limited to U.S. biotech investors.

Global

Low; impact confined to NeoGenomics shareholders.

Counterpoint

What could challenge this read

The modest upside may already be priced in; investors could wait for stronger catalyst.

Key entities

company
NeoGenomics
U.S. listed cancer diagnostics firm (ticker NEO).
analyst
StoneX
Research firm issuing the Buy rating.

Read at source ← All news

OCT 15

$ONMed

Onsemi started at Buy at StoneX, sees 54% upside on chip growth (ON:NASDAQ)

StoneX initiated coverage of ON Semiconductor (ON) with a Buy rating, citing potential benefits from semiconductor demand recovery and growth in automotive and AI data center power systems. The stock is down 3% in premarket trading.

seekingalpha.com1 min

OCT 15

$ONMed

ON Stock Draws Bullish Initiation From StoneX — Analyst Sees Nearly 50% Upside On Broadening Chip Recovery

Onsemi (ON) guided Q3 revenue between $1.65B and $1.75B, up from $1.6B in Q2. StoneX initiated coverage with a bullish outlook, suggesting nearly 50% upside. Retail sentiment on Stocktwits is 'extremely bearish,' despite a 29% year-to-date rally for ON shares, compared to a 65% rise in the iShares Semiconductor ETF (SOXX).

finance.yahoo.com1 min

OCT 14

$DPZMed

StoneX maintains Buy rating on Domino's Pizza, $400 price target

StoneX maintained a Buy rating on Domino's Pizza (DPZ) with a $400 price target, implying a 35.1% upside from the Oct 13 close. The firm cited strong traffic growth drivers and attractive valuation relative to historical ranges. Recent analyst price targets for DPZ range from $320 to $425.

tradingview.com1 min

OCT 12

$SECZMed

Securitize Price Target Rises 50% to $18 at StoneX

StoneX raised its price target for Securitize (NYSE: SECZ) to $18 from $12, citing its expansion into blockchain-based securities markets. The company launched a platform for trading tokenized U.S. stocks, including Apple, Nvidia, Microsoft, and Tesla. Securitize reported $4.3B in tokenized assets under management and $5.3B in transaction volume, but revenue declined 5% to $14.4M with a net loss of $21.7M.

tronweekly.com2 min

OCT 7

$NEOMed

Piper Sandler reiterates Neogenomics stock rating on service strength

Piper Sandler reiterated an Overweight rating on Neogenomics (NEO), citing its competitive position in the community oncology lab market. The firm highlighted the company's service and menu offerings, with NEO ranking first in menu completeness, turnaround, and service. NEO's stock has fallen 10% to $16.42, despite an 83% return over the past year. Recent earnings exceeded expectations, with adjusted earnings of $0.05 per share and revenue of $202 million.

investing.com2 min

OCT 6